Hers Tirzepatide Review: Cost & Honest Verdict (2026)

Hers (forhers.com) is part of Hims & Hers Health, Inc. (NYSE: HIMS), a publicly traded company — genuinely one of the largest and best-capitalized telehealth brands on this entire roster. This review attempted to independently verify current pricing directly against forhers.com and was blocked by a Cloudflare bot-detection challenge.

Live verification was blocked

This review attempted to independently confirm Hers's current pricing and program details directly against forhers.com. The site returned a security-challenge response with a Cloudflare "Just a moment..." bot-detection challenge, blocking automated verification entirely. Every figure below was last verified on July 20, 2026. Visit forhers.com directly to confirm current terms before committing.

What Hers is

Hers is the women-focused telehealth brand from Hims & Hers Health, Inc. — a publicly traded company (NYSE: HIMS) with a broad multi-condition platform spanning weight loss, dermatology, mental health, and sexual health. Its weight-loss program is structured on a 6-month plan.

What Hers costs

Pricing starts around $299/month at the starting dose, plus a separate fee. This review's roster data on Hers is notably thin given the company's public profile — confirm current pricing tiers and specific product names directly on forhers.com.

The brand-vs-compounded question

Hers has offered both compounded GLP-1 access and, at various points, brand-name pathways — its exact current offering has shifted over time as the compounded-GLP-1 regulatory landscape has changed industry-wide since 2024-2025. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture, since this affects large public telehealth brands like Hers as much as smaller compounded-only sellers.

How the care model holds up

Hers's real strength: being part of a large, publicly traded, well-resourced company with a broad multi-condition platform — a fundamentally different risk profile than the smaller, less-capitalized providers that make up most of this site. The trade-off for this specific review: this review's roster data is thin relative to the company's actual public profile, and this review's own live verification attempt was blocked by Cloudflare, meaning the specific current pricing and product details couldn't be independently confirmed this check. As with any GLP-1 program, confirm the current specific product, price, and terms directly on forhers.com before committing; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-1¹, and better than semaglutide head-to-head² — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

Hers's backing by a large, publicly traded company is a genuine structural strength, but this review couldn't independently verify current pricing or product specifics — confirm directly on forhers.com. For a provider with more of this review's own live verification behind it, compare CoreAge Rx or BiltRx. See our best tirzepatide providers ranking for the full field.